Business Wire

China's Online Mutual Aid Market Expected to Triple to 450 Million Users by 2025

7.5.2020 10:39:00 EEST | Business Wire | Press release

Share

By 2025, China's online mutual aid industry is expected to reach 450 million users, or nearly 32% of the country’s population, three times the number of current users, according to the Online Mutual Aid Industry White Paper published today by the Research Institute of Ant Group (“the Institute”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200507005383/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

White Paper Predicts Chinese Online Mutual Aid Market to Triple by 2025 (Graphic: Busness Wire)

The industry white paper, the first of its kind in China, surveyed over 58,000 users of online mutual aid on their perceptions of the industry. Nearly 80% of the respondents felt that online mutual aid platforms strengthened their sense of security. Over 53% also stated that they would consider enrolling their family members in online mutual aid programs.

Users of online mutual aid programs in China are primarily from low-income or middle-income households, according to the white paper. Among those surveyed, who took part in March this year by responding to an online questionnaire, 80% earn less than RMB 8,333 (USD 1,180) per month while 72% come from third or lower-tier cities and rural areas.

“Online mutual aid platforms have become a complementary force in China’s comprehensive healthcare system, which is comprised of both essential public coverage for all citizens and commercial health insurance,” said Zheng Bingwen, Director of the World Social Security Center at the Chinese Academy of Social Sciences and one of the advisers to the white paper.

The reimbursement rate of China’s serious disease insurance scheme, part of the public healthcare system, is capped at 60%1, leaving a portion that patients still need to pay themselves. According to the white paper, online mutual aid programs serve as a complement by further reducing out-of-pocket expenses accrued in the treatment of critical illnesses, bringing it from 40% to below 20% for patients solely dependent on public healthcare coverage.

The white paper estimates that more than 150 million users had enrolled in various online mutual aid programs in China as of the end of 2019, of which over 100 million use Xiang Hu Bao, the online mutual aid platform housed on Alipay, the world's leading open digital lifestyle platform.

Amid the Covid-19 outbreak, Xiang Hu Bao in February also introduced a temporary one-time protection scheme free of charge for all participants, offering a payout of up to RMB 100,000 (USD 14,000) if someone who takes part passes away from the infection. Payouts were entirely borne by Ant Group and Xiang Hu Bao participants did not need to bear the cost.

“As awareness and concerns about health-care needs grows in China, especially since the Covid-19 outbreak, public demand for more comprehensive and diversified healthcare coverage will continue to rise,” said Ming Yin, Vice President of Ant Group. “Online mutual aid platforms will have an increasingly important role to play in providing a basic health plan for people, who can then choose from a wide range of healthcare services and policies.”

“We are committed to serving more users across China and providing them with inclusive mutual aid programs tailored to their specific needs,” Mr. Yin said.

While nearly 70% of online mutual aid participants surveyed in the white paper said they were not covered by commercial health insurance, over 42% said they intend to purchase such insurance products in the future.

This finding is in line with a survey conducted by FT Confidential Research2 in June 2019, which found that 33% of Xiang Hu Bao’s participants intended to buy a critical illness insurance product over the next six months, versus only 22% of those who do not use the platform.

About Xiang Hu Bao

Xiang Hu Bao, which literally means “mutual protection,” was launched in October 2018 and provides its participants with a basic health plan covering 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants equally share the risk of becoming critically ill and collectively bear the related medical expenses. On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof and helps to increase the platform’s transparency, differentiating itself from other mutual aid platforms. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have a wider range and depth of coverage.

About Alipay

Alipay is the world's leading open digital lifestyle platform operated by Ant Financial Services Group (Ant Group). In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019. Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.

Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.

1 Source: http://www.xinhuanet.com/english/2019-05/12/c_138052821.htm

2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Bell Wang
E: yixing.wl@antfin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye